This review summarises the key clinical features of septo-optic dysplasia (SOD), the significant inroads that progress in genetics has made into our understanding of the aetiology of the condition over the last decade, and the pitfalls and challenges that we face in the management of these phenotypically variable patients.
INTRODUCTION
The diagnosis of septo-optic dysplasia (SOD) is a clinical one and can be made when two or more features of the classical triad of (i) optic nerve hypoplasia, (ii) pituitary hormone abnormalities and (iii) midline brain defects, including agenesis of the septum pellucidum and/or corpus callosum, are present. 9 It is a rare congenital anomaly, equally prevalent in males and females, and more common in infants born to younger mothers, with a reported incidence of 1 in 10 000 live births. 1, 10 CLINICAL OVERVIEW Septo-optic dysplasia, previously termed de Morsier syndrome, was first described by Reeves in 1941 as an absence of the septum pellucidum in association with optic nerve abnormalities. 11, 12 Subsequently, an association with pituitary dysfunction was described. 13 Classically the diagnosis of SOD can be made clinically when two or more features of the classical triad (see above) are present. Morishima and Aranoff 14 cite that B30% of SOD cases have complete manifestations, 62% have the complication of hypopituitarism and 60% have an absent septum pellucidum. Isolated features of the triad do not fulfil the diagnostic criteria for SOD, although debate is ongoing as to whether they represent milder cases of the SOD spectrum. 15 The heterogeneous nature of the condition and the variable association with different clinical features led Polizzi et al 16 to suggest that SOD should be renamed SOD complex. Debate is ongoing regarding the correct nomenclature, but for the purposes of this review article, we shall use the classical definition of SOD outlined above. 17 There is a wide variation in the severity of the clinical features found, and in their association with other diagnoses, which follows no clear pattern (Figure 1 ). The main reported clinical findings are hypopituitarism (62-80%), with growth hormone deficiency being the commonest endocrine abnormality, visual impairment (23% significant visual impairment) and developmental delay (more common in children with bilateral (57%) as opposed to unilateral optic nerve hypoplasia (32%)). 18 Seizures, developmental delay and cerebral palsy are the most frequent neurological associations. 19 Pituitary hormone insufficiencies may evolve over time necessitating life-long medical follow-up.
DIAGNOSTIC APPROACHES
Septo-optic dysplasia can present at birth in association with multiple congenital abnormalities or much later on when growth failure occurs in a child also noted to have visual abnormalities (although not necessarily as may just have growth failure with mild undetected visual abnormalities). 15 The child may present with strabismus, nystagmus, or other visual abnormalities. In the majority of cases, the earlier the diagnosis is made the better the outcome, as untreated hormonal abnormalities place an additional neurodevelopmental burden on a child already compromised by visual impairment, and also place the patient at risk of hypoglycaemia, adrenal crises and consequently death. Clinically the diagnosis should be suspected in newborns with hypoglycaemia, jaundice, a microphallus with or without undescended testes and nystagmus with or without associated midline abnormalities such as cleft palate. In these infants, baseline endocrine tests should be performed as outlined below and an ophthalmology referral made. MRI brain images in conjunction with dynamic studies of pituitary function can then be used to confirm the diagnosis. Hormonal insufficiencies should be treated, and early referral both to a neurodevelopmental team with an interest in visual impairment and to a tertiary centre with expertise in managing these children made. A summary of key points to note while taking the history, undertaking 5. Ask about fluid intake: if excessive, measure paired fasting plasma and urine osmolalities; may need to perform water deprivation test to confirm diagnosis of diabetes insipidus.
MOLECULAR AND GENETIC BASIS OF THE DISEASE
The association of abnormalities of the forebrain found in SOD is likely to reflect an early forebrain developmental abnormality, occurring at 4-6 weeks of gestation, a critical period of morphogenesis for the anterior neural plate. Improved understanding of the development of the pituitary gland and forebrain, and the identification of transcription factors important in this process has led to the discovery of genes (so far only two), which when mutated cause SOD. HESX1, a paired-like homeobox gene, which acts as a transcriptional repressor, is one of the earliest markers of murine pituitary development. The study of Hesx1 null mice identified it as a possible candidate gene for SOD, and subsequent investigation of the human homologue HESX1 (OMIM 601802) has led to the identification of five homozygous (autosomal recessive inheritance) and eight heterozygous (autosomal dominant inheritance) pathogenic mutations 3,4 ( Table 1 ). The homozygous mutations are fully penetrant, whereas heterozygous mutations are variably penetrant and usually associated with a milder phenotype. 22, 23 Mutations have also been identified in SOX2 in association with severe bilateral eye abnormalities (anophthalmia, microphthalmia) and defects of the corpus callosum with anterior pituitary hypoplasia. 24 Additional features described in association with SOX2 mutations include developmental delay, short stature, oesophageal atresia, male genital tract abnormalities and sensorineural hearing loss. 25 Establishing the genotype not only furthers our understanding of the aetiology of SOD but also aids patient management, enabling accurate genetic counseling and early diagnosis.
Currently genetic abnormalities are identified in o1% of the patients, with the aetiology of SOD remaining unclear in the majority of patients. This has led to debate as to other factors, which may also have a role in the pathogenesis of SOD. Many studies have reported an increased prevalence of antenatal drug and alcohol abuse and younger maternal age in SOD cohorts. 2, 26 This in combination with the pattern of neurological abnormalities found in individuals with SOD led Lubinsky 27 to suggest that septo-optic dysplaisa occurs secondary to a vascular disruption sequence. 28 It is likely that although other genetic abnormalities are likely to be identified in the future, environmental factors such as drugs, alcohol and anterior cerebral artery supply during the neonatal period may also play a significant role in the aetiology of SOD.
MANAGEMENT
Patients with SOD need regular (at least six-monthly) ongoing followup by a multi-disciplinary team. Management centres on identifying evolving hormonal insufficiencies and optimising hormonal replacement, ensuring appropriate ophthalmological follow-up, instigating neurodevelopmental support early on in life from a team with experience in looking after children with visual impairment, and monitoring closely for the development of other associated features such as autism and obesity.
Genetic counseling
The majority of cases of SOD are sporadic, and therefore, in the absence of any family history of the disorder, the recurrence risk is o1%. In consanguineous families, the likelihood of recessive inheritance is significantly higher, and parents should be counseled that even if there is no identifiable genetic mutation, the likely recurrence risk is one in four. SOX2 mutations are de novo with a very low risk of recurrence. The variable penetrance and phenotypes associated with dominant HESX1 mutations make genetic counseling difficult, as it would be impossible to predict whether the mutations would be associated with a distinct phenotype.
CONCLUSION
Septo-optic dysplasia remains a rare, heterogeneous and phenotypically variable disorder, which can pose significant diagnostic challenges; namely, the delay in diagnosis, the later development of hormonal deficiencies and the presence of other phenotypic features such as obesity and autism. Challenges such as this highlight the need for the careful longitudinal follow-up of large patient cohorts, to enable the development of more accurate diagnostic criteria and ongoing management plans.
Research is ongoing into the genetic aetiology of SOD. To date, the overall frequency of pathological genetic mutations identified in the SOD population is low, with no mutations identified in many familial cases, suggesting that mutations in other known or unknown genes may have a role in this complex disorder. Our knowledge and understanding of the transcriptional factors involved in the development of the forebrain remains rudimentary and future work identifying these may uncover other molecular causes for SOD. The multi-faceted interaction between these transcription factors and the environment is also likely to play a role in the significant variability in phenotype and penetrance associated with SOD. 1, 31 Further investigation of these intricate relationships may help us to better understand the aetiology of this complex disorder, possibly enabling us in the future to develop an improved diagnostic algorithm and to predict which children are likely to go on to develop hormonal abnormalities, developmental problems, and so on.
